A novel self-expandable portal vein stent loaded with 125iodine seeds for the treatment of portal vein tumour thrombosis in hepatocellular carcinoma: Initial results

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPN-16007856

Enrollment

Unknown

Registered

2016-01-28

Start date

2012-10-13

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma

Interventions

1:placement of a novel portal vein stent loaded with 125iodine (125I) seeds

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) age 18-75 years; (2) type II or III PVTT; (3) Child-Pugh classification grade A or B; (4) Eastern Cooperative Oncology Group (ECOG) performance status score less than 3, and (5) willingness and ability to comply with the study.

Exclusion criteria

Exclusion criteria: (1) patients with suspected benign thrombosis; (2) type I or IV PVTT; (3) a locoregional treatment history (surgical resection, stenting, or radiotherapy) for PVTT; (4) a white blood cell concentration of less than 3000 cells per µL, and (5) renal inadequacy defined as a glomerular filtration rate of less than 30 mL/min per 1.73 m2 (chronic kidney disease stage 4-5).

Design outcomes

Primary

Measure	Time frame
complications;	—

Secondary

Measure	Time frame
technical success;survival time;stent patency;recanalization success;	—

Countries

China

Contacts

Public ContactGao-Jun Teng

gjteng@vip.sina.com+86 25 83272121

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026